Form 8-K

8-K — Inmune Bio, Inc.

Accession: 0001213900-26-064144

Filed: 2026-06-02

Period: 2026-06-02

CIK: 0001711754

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0293325-8k_inmune.htm (Primary)

EX-99.1 — PRESS RELEASE DATED JUNE 2, 2026 (ea029332501ex99-1.htm)

GRAPHIC (ea0293325_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0293325-8k_inmune.htm · Sequence: 1

false

0001711754

2026-06-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 2, 2026

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

Nevada

001-38793

47-5205835

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

225 NE Mizner Blvd., Suite 640, Boca Raton,

Florida 33432

(Address of Principal Executive Offices) (Zip Code)

(561) 710-0512

(Registrant’s Telephone Number, Including

Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per shares

INMB

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 2, 2026, INmune

Bio Inc. issued a press release announcing results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL

Phase 2 clinical trial of XPro™ (XPro1595) in patients with early Alzheimer's disease encompassing both mild cognitive impairment

(MCI) and mild Alzheimer’s disease dementia.

A copy of the press release is attached as Exhibit

99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits

(d) Exhibits.

99.1

Press Release dated June 2, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMUNE BIO INC.

Date: June 2, 2026

By:

/s/ David Moss

Name:

David Moss

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED JUNE 2, 2026

EX-99.1

Filename: ea029332501ex99-1.htm · Sequence: 2

Exhibit 99.1

INmune

Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial

XPro1595 showed a highly

significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200),

demonstrating broad tissue-level target engagement

and treatment-related biological effect.

Efficacy was further

strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating

INmune’s precision-medicine

approach and directly aligning with the design of the Phase 2b/3 registrational program.

BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE)

-- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced

results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL Phase 2 clinical trial of XPro™

(XPro1595) in patients with early Alzheimer’s disease encompassing both mild cognitive impairment (MCI) and mild Alzheimer’s disease

dementia.

The new MRI findings add to a growing body

of evidence supporting XPro™’s precision-medicine development strategy, including the peer-reviewed publication of the Phase

2 MINDFuL results in NPJ Dementia, FDA End-of-Phase 2 alignment on an integrated Phase 2b/3 registrational pathway, and the recent grant

of FDA Fast Track designation for XPro™ in early Alzheimer’s disease.

CJ Barnum, VP of Neuroscience at INmune Bio,

further added, “What we are seeing in MINDFuL is consistency across nearly every domain we measured: cognition, neuropsychiatric

symptoms, blood biomarkers, patient-reported outcomes, and now both MRI measures of brain quality, gray matter and white matter. The chi-separation

result is the latest signal in that convergent picture, and it carries an additional layer of significance: across multiple independent

preclinical models, XPro’s most reliable and reproducible effect has been on myelin biology. The MINDFuL chi-separation result demonstrates

a treatment effect on myelin in the full study population that strengthens in patients with elevated inflammatory biomarkers. This is

not a surprise finding. It is exactly what the preclinical work predicted. We look forward to presenting the complete dataset at AAIC

2026.”

BACKGROUND: White Matter Opportunity in

Neurodegenerative Disease

Across multiple independent preclinical models

of demyelination and neurological injury, white matter has consistently emerged as the most reliable and reproducible target of XPro™

response, with clear, documented effects on myelin volume and quality. While historical industry efforts in AD have focused heavily on

gray matter pathology, white matter (WM) degeneration and myelin loss are increasingly recognized as fundamental, early contributors to

cognitive decline. This structural degradation is not unique to Alzheimer’s; it represents a primary pathological signature across a broad

spectrum of neurological and neurodegenerative conditions such as Multiple Sclerosis (MS), Vascular Dementia, traumatic brain injury,

and many rare CNS diseases where neuroinflammation drives destruction of oligodendrocytes and myelin integrity.

Chi-separation MRI was included in the MINDFuL

Phase 2 trial as a target engagement biomarker for white matter. This method was chosen given that the trial enrolled patients with MCI

and mild AD, the disease stage at which white matter abnormalities are prominent and highly clinically relevant. Chi-separation is a recently

validated imaging technique that resolves key challenges of conventional MRI myelin measurement and can be deployed across standard multi-site

clinical infrastructure without requiring specialty scanners, making it a methodologically superior and operationally scalable measure

of white matter biology.

Statistically Significant Biomarker Results

The blinded analysis, performed by an independent

imaging core laboratory, revealed statistically significant treatment effect on myelin:

● Full mITT Population (N=200): After 24 weeks of treatment, XPro™-treated

participants showed a statistically significant difference in myelin compared to placebo (p=0.0028) with a medium effect

size (Cohen’s d=0.46). This effect across the full treatment population reproduces XPro™’s most reliable preclinical

signature, establishing target engagement in AD patients with a high degree of confidence.

● Biomarker-Enriched AD Population (N=100): In patients with amyloid-positivity

and two or more elevated inflammatory biomarkers at baseline, the treatment effect strengthened further to a medium-to-large effect size

(Cohen’s d=0.59; p=0.0098). This is the patient profile most directly aligned with XPro™’s anti-neuroinflammatory

mechanism.

“A statistically significant treatment

effect on white matter across the full mITT population, strengthening further in inflammation-enriched patients, tells us that XPro™

is doing exactly what it is designed to do, with increased effect in patients we intend to treat in the registrational study,” said

David Moss, Chief Executive Officer of INmune Bio. “Importantly, by successfully targeting neuroinflammation to preserve and

potentially repair white matter, these data do more than validate our current program, they provide a robust mechanistic foundation that

expands the opportunities for XPro™ across a spectrum of other neurodegenerative and neuroinflammatory disease states where pathology

is driven by the same inflammatory cascade. With FDA Fast Track designation in hand, End-of-Phase 2 alignment secured, and an additional

imaging biomarker result that further reinforces our patient selection strategy, we have systematically addressed several of the key uncertainties

that have historically derailed programs in this space. We are building the registrational program on our strongest scientific footing

to date and for our broader pipeline potential with XPro.”

AAIC 2026 Presentation

INmune Bio will present the complete chi-separation

dataset from the MINDFuL study, including longitudinal trajectory analysis, subgroup characterization, dose-response analyses, and mechanistic

interpretation at the Alzheimer’s Association International Conference (AAIC) 2026 which will take place July 12–15, 2026 in London,

UK. The presentation will also include data from complementary advanced MRI endpoints in the MINDFuL imaging package. Additional details

will be announced following the presentation.

Accelerated Registration Program Architecture

Following a successfully completed End-of-Phase

2 meeting, INmune Bio has secured regulatory alignment with the FDA on the design of its upcoming registrational program, establishing

a clear, de-risked pathway toward commercial submission. Supported by FDA Fast Track designation granted on May 14, 2026, the Phase 2b/3

seamless adaptive trial is engineered to support the registration of XPro™ in patients with early Alzheimer’s disease who carry

biomarkers of inflammation.

The registrational strategy is also supported

by the favorable safety profile observed in the Phase 2 MINDFuL trial, including no observed ARIA-E or ARIA-H, an important differentiating

feature for a disease-modifying Alzheimer’s program focused on neuroinflammation rather than amyloid clearance.

● Phase 2b Adaptive Advancement: The Phase 2b portion of the study

will utilize the Early Alzheimer’s Disease Cognitive Composite (EMACC) and plasma pTau217 as rigorous, decision-gating endpoints. These

metrics will dictate the adaptive advancement of the program into the Phase 3 cohort.

● Phase 3 Registrational Evaluation: The Phase 3 portion is expected

to evaluate definitive clinical outcomes, including the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB), which the FDA has

raised no objections to using as the sole primary efficacy endpoint for the Phase 3 registrational portion of the program.

About XPro1595

XPro1595 is a next-generation inflammatory

cytokine modulator that neutralizes soluble TNF (sTNF) without affecting transmembrane TNF (tmTNF) or its receptors. This selective targeting

is designed to reduce neuroinflammation, a key driver of neurodegeneration in Alzheimer’s disease, while maintaining the protective

immune functions of the body.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ:

INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving

beyond early-stage exploration, the company’s clinical-development strategy centers on advanced precision medicine, matching drug

mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage

product platforms toward registrational milestones:

1. CORDStrom™: A

proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform engineered to address the historical

clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in Recessive Dystrophic

Epidermolysis Bullosa (RDEB), the platform is transitioning to regulatory filing phases, with a Marketing Authorization Application (MAA)

scheduled for the UK MHRA and EU EMA in 2026, alongside a planned U.S. Biologics License Application (BLA) submission.

2. XPro™: A

Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation

without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment

from an End-of-Phase 2 meeting, XPro™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched

early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline

and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there

is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development

or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data,

including trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or

commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private

Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject

to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those

described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™,

pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical

trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be

any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved.

The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks

and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional

funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;

and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission,

including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current

Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that

may arise after the date of this release.

INmune

Bio Contacts:

David

Moss

Chief Executive Officer

(561) 710-0512

info@inmunebio.com

Daniel

Carlson

Head of Investor Relations

(415) 509-4590

dcarlson@inmunebio.com

GRAPHIC

Filename: ea0293325_ex99-1img1.jpg · Sequence: 3

Binary file (1770 bytes)

Download ea0293325_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 02, 2026

Entity File Number

001-38793

Entity Registrant Name

INMUNE BIO INC.

Entity Central Index Key

0001711754

Entity Tax Identification Number

47-5205835

Entity Incorporation, State or Country Code

Entity Address, Address Line One

225 NE Mizner Blvd.

Entity Address, Address Line Two

Suite 640

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33432

City Area Code

561

Local Phone Number

710-0512

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per shares

Trading Symbol

INMB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration